India Ratings affirms Cipla’s long-term issuer rating at ‘AAA’

09 Oct 2014 Evaluate

Credit rating agency, India Ratings & Research has affirmed Cipla’s long-term issuer rating at ‘AAA’ with a stable outlook. The rating agency has also affirmed the company’s Rs 1000 crore commercial paper/short-term debt programme at ‘A1+’.

Meanwhile, the rating agency has withdrawn the ‘AAA(exp)’ rating assigned to Cipla’s proposed Rs 2000 crore non-convertible debenture issuance (NCD) programme on September 24, 2013 since the company has not proceeded with the issuance.

The ratings reflect the company’s strong business profile as a leading generics player in the domestic market. Cipla’s domestic product sales account for 45% of the turnover while exports account for 55% presently.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.

Cipla Share Price

1500.00 -7.25 (-0.48%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×